Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | S. Pierce | J. Khoury | N. Pemmaraju | N. Short | S. Konoplev | R. Mehta | P. Reville | K. Sasaki | M. Yilmaz